多西他赛联合表柔比星/吡柔比星新辅助治疗对乳腺癌患者血清肿瘤标志物的影响  

Effect of docetaxel combined with neoadjuvant therapy of epirubicin/pirarubicin on serum tumor markers in patients with breast cancer

作　　者：黄河清[1] 

机构地区：[1]广东省东莞市人民医院乳腺科,广东东莞523059

出　　处：《中国医药科学》2017年第20期39-41,78,共4页China Medicine And Pharmacy

摘　　要：目的探讨多西他赛(DOC)联合表柔比星(EPI)或吡柔比星(THP)新辅助治疗对乳腺癌患者血清肿瘤标志物的影响。方法回顾分析我院乳腺科2014年1月~2016年12月之间收治100例乳腺癌患者的临床资料,按照化疗方案的不同将其分为对照组和观察组,对照组接受卡培他滨联合EPI或THP方案治疗,观察组接受DOC联合EPI或THP方案治疗,比较分析两组患者临床疗效及对血清肿瘤标志物的影响。结果对照组患者总有效率为58.0%,观察组患者总有效率为74.0%,两组比较差异有统计学意义(P<0.05);两组患者治疗前CEA、CA125、CA153肿瘤标志物比较差异无统计学意义(P>0.05);观察组、对照组治疗后CEA、CA125、CA153肿瘤标志物均明显低于组内治疗前,且差异均有统计学意义(P<0.05),观察组患者治疗后CEA、CA125、CA153肿瘤标志物均明显低于对照组治疗后,且差异均有统计学意义(P<0.05)。结论乳腺癌患者接受多西他赛联合表柔比星或吡柔比星辅助化疗效果显著,有助于降低血清肿瘤标志物,值得临床推广。Objective To investigate the effect of docetaxel（DOC） combined with neoadjuvant therapy（EPI） of epirubicin（EPI） or pirarubicin（THP） on serum tumor markers in patients with breast cancer. Methods The clinical data of 100 patients with breast cancer in galactophore department of our hospital were analyzed retrospectively, and were divided into control group and observation group according to the different chemotherapy treatment methods. The patients of control group were given the combination of capecitabine with EPI or THP programme therapy, the patients of observation group were given DOC combined with EPI or THP programme therapy, and the clinical efficacy and the impact of serum tumor markers of two groups were compared. Results The total effective rate of control group was 58.0%, while the total effective rate of the observation group was 74.0%, and the difference between the two groups was statistically significant（P 〈 0.05）. Before treatment, there was no statistically significant difference between the tumor markers of CEA, CA125 and CA153 of two groups （P 〉 0.05）. The tumor markers of CEA, CA125 and CA153 in the observation group and the control group were significantly lower than those before treatment respectively, and the differences were statistically significant（P 〈 0.05）. And the tumor markers of CEA, CA125 and CA153 in the observation group were significantly lower than those in the control group（P 〈 0.05）, and the differences were statistically significant（P 〈 0.05）. Conclusion The efficacy of docetaxel combined with epirubicin or pirarubicin in the treatment of breast cancer is significant, which can helpful to reduce the serum tumor markers and deserve clinical promotion.

关 键 词：乳腺癌 辅助化疗 多西他赛 表柔比星 吡柔比星 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]